<DOC>
	<DOC>NCT02491983</DOC>
	<brief_summary>This is an international, randomized, open-label, controlled, multicenter phase II clinical trial to investigate and compare the safety and efficacy of palbociclib combined with fulvestrant or letrozole in women with ER+, HER2- locally advanced or metastatic breast cancer.</brief_summary>
	<brief_title>Study to Evaluate the Efficacy and Safety of Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Locally Advanced or Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Palbociclib</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Women 18 years or older with metastatic or locally advanced disease, not amenable to curative therapy Confirmed diagnosis of HR+/HER2 breast cancer Postmenopausal status No prior chemotherapy line in the metastatic setting Measurable disease defined by RECIST version 1.1, or nonmeasurable disease Eastern Cooperative Oncology Group (ECOG) PS 01 Adequate organ and marrow function, resolution of all toxic effects of prior therapy or surgical procedures Confirmed diagnosis of HER2 positive disease Patients with rapidly progressive visceral disease or visceral crisis. Locally advanced breast cancer candidate for a radical treatment. Prior (neo)adjuvant endocrine treatment with DFI â‰¤ 12months from completion of treatment. Major surgery within 4 weeks of start of study drug Serious concomitant systemic disorder incompatible with the study Known active uncontrolled or symptomatic CNS metastases</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>metastatic breast cancer</keyword>
	<keyword>Endocrine receptors positive</keyword>
	<keyword>HER-2 negative</keyword>
</DOC>